P229 Do CFTR modulators interfere with microbiological diagnosis? - Université de Reims Champagne-Ardenne Access content directly
Conference Poster Year : 2024

P229 Do CFTR modulators interfere with microbiological diagnosis?

G. Héry-Arnaud
S. Vallet
  • Function : Author
M.-E. Bougnoux
  • Function : Author
E. Cardot-Martin
  • Function : Author
S. Cassaing
  • Function : Author
A. Chesnay
  • Function : Author
L. Crémet
  • Function : Author
A. Doléans-Jordheim
  • Function : Author
C. Dupont
  • Function : Author
A. Ferroni
  • Function : Author
J.-P. Gangneux
  • Function : Author
F. Garnier
  • Function : Author
H. Guet-Revillet
  • Function : Author
L. Handala
  • Function : Author
J.-L. Herrmann
  • Function : Author
K. Jeannot
  • Function : Author
L. Lachaud
  • Function : Author
S. Le Gal
  • Function : Author
P. Lehours
  • Function : Author
J.-L. Mainardi
  • Function : Author
L. Millon
  • Function : Author
C. Piau
  • Function : Author
F. Persat
  • Function : Author
I. Villena
  • Function : Author
H. Yéra
  • Function : Author
L. Velo-Suarez
  • Function : Author
L. Delhaes
  • Function : Author

Abstract

Objectives: The widespread introduction of modulator therapies may force us to reconsider our models of cystic fibrosis (CF) airway microbiology. Indeed, by improving airway clearance, CFTR modulators are likely to lead to substantial changes in the cyto-microbiological parameters of sputum from people with CF (pwCF). Our aim was to assess the real impact of modulators on the fundamentals of microbiological diagnosis. Methods: During 2023, 13 French CF centers each prospectively collected between 28 and 32 sputum samples from pwCF. For each sample, the volume of sputum collected was recorded, along with the cytological quality of the sputum and the results of microbiology. Routine microbial cultures were performed according to the French standard operating procedures. These data were compared according to the 2 groups: pwCF with CFTR modulator treatment (M+) or not (M-). Results: A total of 392 pwCF and samples were analysed. The mean age of the cohort was 20.3 +/− 14.3 years, with 215 males and 177 females. Among pwCF, 64.5% were M+, including 87% on Kaftrio®, and 35.5% were M-. The median volume of sputum collected was 1 mL. Comparison of the two patients’ groups identified no statistically significant difference in volume collected, polynuclear count, or prevalence of the following pathogens: Haemophilus influenzae, Staphylococcus aureus, Pseudomonas aeruginosa (mucoid or not), Stenotrophomonas maltophilia, Achromobacter spp. Enterobacterales, and Aspergillus fumigatus. Conclusion: The lack of difference in the cyto-microbiological criteria between M+ and M− patients seems to not reflect the lack of impact of CFTR modulators, but rather the fact that the patients who continue to be sampled correctly are the exacerbating pwCF in whom modulators do not change drastically the airways microbiology. The number of patients for whom sputum collection was not possible, making analysis impossible, remains to be determined. The data will be analysed by age group.
No file

Dates and versions

hal-04609383 , version 1 (12-06-2024)

Identifiers

Cite

G. Héry-Arnaud, S. Vallet, M.-E. Bougnoux, E. Cardot-Martin, S. Cassaing, et al.. P229 Do CFTR modulators interfere with microbiological diagnosis?. ECFC (European Cystic Fibrosis Conference), Jun 2024, Glasgow, United Kingdom. 23, pp.S139, 2024, ⟨10.1016/S1569-1993(24)00533-2⟩. ⟨hal-04609383⟩

Collections

URCA P3CELL
13 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More